InsiderTrades.com logo
The #1 Crypto for AI
From Weiss Ratings   |   Ad
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Learn more about it by watching THIS NOW.

James Daly Biography and Net Worth

Director of Madrigal Pharmaceuticals
  • Phone
  • Email
  • Website


On June 27, 2019, Madrigal’s Board of Directors appointed James M. Daly as a member of our Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and also currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, and Halozyme Therapeutics. He previously served on the board of directors of Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a publicly-held biopharmaceutical company, or Incyte, from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK), where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.

What is James M. Daly's net worth?

The estimated net worth of James M. Daly is at least $279,721.02 as of April 1st, 2024. Mr. Daly owns 1,198 shares of Madrigal Pharmaceuticals stock worth more than $279,721 as of September 22nd. This net worth approximation does not reflect any other assets that Mr. Daly may own. Learn More about James M. Daly's net worth.

How do I contact James M. Daly?

The corporate mailing address for Mr. Daly and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on James M. Daly's contact information.

Has James M. Daly been buying or selling shares of Madrigal Pharmaceuticals?

James M. Daly has not been actively trading shares of Madrigal Pharmaceuticals over the course of the past ninety days. Most recently, James M. Daly sold 32,489 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $102.77, for a transaction totalling $3,338,894.53. Following the completion of the sale, the director now directly owns 1,198 shares of the company's stock, valued at $123,118.46. Learn More on James M. Daly's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 4 times. They purchased a total of 226,067 shares worth more than $43,382,043.47. During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 188,584 shares worth more than $40,797,262.98. The most recent insider tranaction occured on September, 9th when CEO William John Sibold sold 6,363 shares worth more than $1,551,490.29. Insiders at Madrigal Pharmaceuticals own 23.9% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 9/9/2024.

James M. Daly Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Sell32,489$102.77$3,338,894.531,198View SEC Filing Icon  
See Full Table

James M. Daly Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows James M Daly's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $233.49
Low: $233.00
High: $244.23

50 Day Range

MA: $255.47
Low: $233.00
High: $287.24

2 Week Range

Now: $233.49
Low: $119.76
High: $299.98

Volume

530,021 shs

Average Volume

440,606 shs

Market Capitalization

$4.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The #1 Crypto for AI
From Weiss Ratings   |   Ad
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Learn more about it by watching THIS NOW.